Artiva
PublicArtiva is now publicly traded
The data on this page reflects Artiva's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jul 18, 2024
Last Round
Series B
Feb 26, 2021
Total Funding Raised
$365M
Company Overview
Artiva Biotherapeutics (NAS: ARTV) is a biopharmaceutical company focused on developing off-the-shelf, allogeneic NK cell therapies for treating hematologic malignancies and solid tumors.
Sector
Biotech
AI Layer
Non-AI
Keywords
Artiva Comparables
Compare Artiva with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Shoreline Biosciences | 82% | |
| Therabest | 81% | |
| HebeCell | 81% |
Artiva Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jul 18, 2024 | ||||
| Series B | Feb 26, 2021 | ||||
| Series A | Jun 26, 2020 | ||||
| Seed | Mar 1, 2019 |
Artiva Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B |
| Jefferies | IPO |
| Janus Henderson Group | Series B |
| RA Capital Management | Series B, Series A |
| 5AM Ventures | Series B, Series A |
| TD Cowen | IPO |
| Logos Capital | Series B |
Artiva Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access